Net Sales are expected to increase by 14.5 percent Q-o-Q (up 27.2 percent Y-o-Y) to Rs 2902.7 crore, according to ICICI Securities. Glenmark to report net profit at 590 crore up 28.3% quarter-on-quarter.

Glenmark Q3 profit seen up 77%, US biz may lift revenue 33%

For US business, the company may benefit from USD 2.6 billion worth Zetia generic, a cholesterol drug that launched with exclusivity on December 12 in US. Analysts expect the company to make USd 200-250 million from Zetia in 6 months.

Glenmark Pharma Q3 PAT seen up 37% to Rs 310 cr: HDFC Securities

Net Sales are expected to increase by 0.9 percent Q-o-Q (down 27.1 percent Y-o-Y) to Rs 2190 crore, according to HDFC Securities.

Glenmark Q3 PAT seen up 62.6% to Rs 363.5 cr: ICICI Securities

Net Sales are expected to increase by 11.6 percent Q-o-Q (up 39.6 percent Y-o-Y) to Rs 2482.5 crore, according to ICICI Securities.

Expect better performance from core US biz in Q3: Glenmark

Glenn Saldanha says Zetia Generic - a drug to keep a check on cholestrol levels - will be launched on December 12. The launch could see USD 200-250 million in revenues. The company is going to use the money from here to bring down company's debt.

Glenmark Pharma Q2 profit seen up 24% but margin may contract

Glenmark Pharma is expected to report a 24 percent growth in second quarter profit at Rs 245 crore on yearly basis but margin may contract by 160 basis points to 19.4 percent, according to analysts polled by CNBC-TV18.

New products, regulatory approvals to drive growth for Glenmark

The company is expecting strong growth in the current fiscal both from India and US. Major approvals are expected to drive growth for Glenmark, says Chairman and Managing Director Glenn Saldanha.

Sun Pharma's topline may suffer; like Aurobindo, Glenmark:Expert

Surajit Pal of Prabhudas Lilladher talks about Sun Pharma and Glenmark's June quarter earnings.

Glenmark Q1 profit seen up 1.6%, US sales likely at $100 mn

Analysts expect a slowdown in growth for the quarter against preceding quarter (when topline grew 30 percent YoY) due to a slower than estimated growth in India and Latin America businesses.

Glenmark Q1 PAT seen up 43.1% at Rs 204.7 cr: Religare Research

Sales are expected to decrease by 17.9 percent Q-o-Q (up 14.4 percent Y-o-Y) to Rs 1893.6 crore, according to Religare Research.

Glenmark Q1 PAT seen up 43.4% to Rs 205.1 cr: Edelweiss

Net Sales are expected to decrease by 13.7 percent Q-o-Q (up 15.9 percent Y-o-Y) to Rs 1904 crore, according to Edelweiss

Awaiting $45 million from Venezuelan govt: Glenmark Pharma

With the big product launch of Ezetimibe (a cholesterol-lowering drug), company's topline revenue to be over 25 percent, where 45 percent will be contributed by the US and 20-25 percent by the Indian business, says Glenn Saldanha, Chairman & MD of Glenmark Pharmaceuticals.

Glenmark Q4 net seen at Rs 200cr, weak LatAm biz may hurt sales

EBITDA in Q4 may jump to Rs 388.3 crore against Rs 281.4 crore whil operating profit margin may stand at 20.7 percent from 16 percent year-on-year.

See muted Q4 for Dr Reddy's, Glenmark: Prabhudas Lilladher

Two leading pharma companies, Dr Reddy's and Glenmark, are slated to post fourth-quarter earnings today and chances are both firms may disappoint, says Surajit Pal, Pharma Analyst at Prabhudas Lilladher.

Glenmark Q3 profit may surge 95%, US biz likely to pick up

Analysts feel US business is likely to pick up, aiding overall revenue growth of the company. They expect revenue growth of around USD 94-95 million against USD 92.34 million in preceding quarter. The company has received around 12 USFDA approvals in FY16 against 5 each in FY14 & FY15, respectively.

Glenmark Q2 profit seen up 14%, India biz may remain strong

Analysts expect sluggish sales in Russia/CIS & Brazil due to adverse currency movement. Around 10 percent of Glenmark' sales comes in Brazil, Russia & Euro.

Buy Dr Reddys at every dip; cautious on Cipla: IIFL

Given the numbers and the valuations the brokerage house would refrain from hiking the target price for Cipla from the current Rs 1070, Bhavesh Gandhi.

Glenmark Q1 net seen up 15%; US, LatAm, India may drive rev

Analysts expect US growth momentum (that picked up in Q4FY15) to continue in June quarter as well. US business is expected to be USD 92 million against USD 86.16 million in March quarter as approvals in the US picked up.

Sun will turn Ranbaxy profitable; stock fall brief: Angel

Sarabjit Kaur Nangra of Angel Broking is neutral on Cipla as of now because the price has run up ahead of fundamentals.

See 18-20% growth, 10-12 product launches in US: Glenmark

According to CMD Glenn Saldanha, emerging markets will see positive growth for the company in FY16. The company continues to invest in emerging markets.

Glenmark Pharma Q4 profit may jump over 4-fold to Rs 191 cr

Glenmark Pharma's fourth quarter profit is expected to increase 4.4 times year-on-year to Rs 191 crore against Rs 43 crore, according to a CNBC-TV18 poll.

Mixed Q3 nos for pharma so far: Here's what you should buy

Hitesh Mahida is bullish on Cipla, Glenmark and Dr Reddy‘s Laboratories from the large cap pharma space and suggests caution on Lupin for now.

See acceleration in US biz this quarter onwards: Glenmark

Glenmark Pharma reported a 46.92 percent dip in its consolidated net profit at Rs 114.77 crore for the quarter ended December 31, 2014, mainly due to forex losses and increased expenses. The company had posted a profit after tax and minority interest of Rs 216.23 crore for the corresponding period of the previous fiscal.

Glenmark Q3 profit seen down 15.2% to Rs 181.5 cr: Poll

Glenmark Pharma's third quarter profit after tax is expected to fall 15.2 percent year-on-year to Rs 181.5 crore, according to a CNBC-TV18 poll.

India Q2 biz has outperformed; maintain guidance: Glenmark

Glenn Saldanha, chief executive officer, Glenmark says that while the US business has been a drag, India business has been an outperformer for the company.